Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
09/2003
09/09/2003CA2079413C Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use
09/04/2003WO2003073107A2 Neuropeptide receptor and uses thereof
09/04/2003WO2003073062A2 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
09/04/2003WO2003072821A2 Method and nucleic acids for the analysis of a colon cell proliferactive disorder
09/04/2003WO2003072820A2 Method and nucleic acids for the analysis of colon cell proliferative disorders
09/04/2003WO2003072812A2 Method and nucleic acids for the analysis of colorectal cell proliferative disorders
09/04/2003WO2003072801A2 Compositions and method for regulation of calcium-dependent signalling in brain
09/04/2003WO2003072789A2 Microorganisms as carriers of nucleotide sequences coding for cell antigens used for the treatment of tumors
09/04/2003WO2003072768A2 Modified human manganese superoxide dismutase and uses thereof
09/04/2003WO2003072736A2 Reagents and treatment methods for autoimmune diseases
09/04/2003WO2003072732A2 Methods of making hypermutable cells using pmsr homologs
09/04/2003WO2003072725A2 Recombinant negative strand virus rna expression systems and vaccines
09/04/2003WO2003072720A2 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
09/04/2003WO2003072719A2 Metapneumovirus strains and their use in vaccine formulations and as vector for expression of antigenic sequences
09/04/2003WO2003072704A2 RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
09/04/2003WO2003072608A1 Anti-human tenascin monoclonal antibody
09/04/2003WO2003072606A2 Galectin-8and functional derivatives as binding agents for cd44 glycoproteins and methods of use
09/04/2003WO2003072603A2 Long pentraxin ptx3 functional derivatives for preparing an autologous vaccine for the treatment of tumours
09/04/2003WO2003072595A2 Methods and products based on oligomerization of stress proteins
09/04/2003WO2003072580A1 1-[ALKYL], 1-[HETEROARYL)ALKYL] AND 1-[ARYL)ALKYL]-7-(PYRIMIDIN-4-YL)-IMADAZO[1,2-a]PYRIMIDIN-5(1H)-ONE DERIVATIVES
09/04/2003WO2003072579A1 HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL -6,7,8,9- TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES
09/04/2003WO2003072566A1 Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
09/04/2003WO2003072561A1 Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
09/04/2003WO2003072557A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
09/04/2003WO2003072556A1 Glutaminyl based dpiv inhibitors
09/04/2003WO2003072549A1 Farnesyl protein transferase inhibitors as antitumor agents
09/04/2003WO2003072539A1 Phenethanolamine derivatives for treatment of respiratory diseases
09/04/2003WO2003072159A1 N-{5-[4-(4-methyl-piperazino-methyl)­-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents
09/04/2003WO2003072142A1 Method of encapsulating metal complex within liposomes
09/04/2003WO2003072139A1 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
09/04/2003WO2003072137A1 Combinations of (a) an atp- competitive inhibitor of c-abl kinase activity with (b) two or more other antineoplastic agents
09/04/2003WO2003072124A1 Induction method for cell differentiation
09/04/2003WO2003072114A1 Vascular therapeutics
09/04/2003WO2003072108A1 Novel crystalline forms of the anti-cancer compound zd1839
09/04/2003WO2003072107A1 Substituted pyrimidinones and pyrimidinthiones
09/04/2003WO2003072091A1 Therapeutic methods for acute myeloid leukemia
09/04/2003WO2003072082A1 Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
09/04/2003WO2003072063A2 Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
09/04/2003WO2003072062A2 Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
09/04/2003WO2003072060A2 Polypeptide formulation
09/04/2003WO2003072050A2 Prevention of and therapy for radiation toxicity of normal tissues using drugs which block il-1 activity
09/04/2003WO2003072036A2 Treatment methods using anti-cd22 antibodies
09/04/2003WO2003072027A2 Compositions and formulations of 9- nitrocamptothecin polymorphs and methods of use thereof
09/04/2003WO2003071933A2 Novel compositions and methods for cancer
09/04/2003WO2003064472A3 Treatment of ms with goat serum
09/04/2003WO2003062209A3 Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
09/04/2003WO2003057006A3 Use of antibodies against the muc18 antigen
09/04/2003WO2003053224A3 Novel compositions and methods for cancer
09/04/2003WO2003051926A3 Anti-cd7 immunotoxin as fusion protein
09/04/2003WO2003051805A3 Substituted phenyl naphthalenes as estrogenic agents
09/04/2003WO2003048334A3 Immunocytokines with modulated selectivity
09/04/2003WO2003046560A3 Self-assembly molecules
09/04/2003WO2003045313A3 2-aminoquinoline compounds
09/04/2003WO2003037891A8 Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
09/04/2003WO2003030922A3 Bestrophin and bestrophin homologous proteins involved in the regulation of energy homeostasis
09/04/2003WO2003030884A3 Use of solasonine for the treatment of skin tumors
09/04/2003WO2003029423A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
09/04/2003WO2003025162A3 Regulation of human prolyl 4-hydroxylase alpha subunit precursor
09/04/2003WO2003025151A3 Circadian control of stem/progenitor cell self-renewal and differentiation and of clock controlled gene expression
09/04/2003WO2003024967A3 Indolizines as kinase protein inhibitors
09/04/2003WO2003018002A3 Cyclopropyl and cyclobutyl epothilone analogs
09/04/2003WO2003011860A3 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1-DIOXO-1λ6-THIOMORPHOLIN-4-YL)-4-(2-METHYL OR 4-FLUORO-2-METHYL SUBSTITUTED)PHENYL-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE
09/04/2003WO2003001212A3 A method for diagnosing a person having multiple sclerosis
09/04/2003WO2002098918A3 Novel targets for a therapeutic intervention in ebv related diseases
09/04/2003WO2002097395A3 P-cadherin as a target for anti-cancer therapy
09/04/2003WO2002088106A3 Cysteine protease inhibitors
09/04/2003WO2002082076A3 Renal cell carcinoma tumor markers
09/04/2003WO2002079465A3 Micromonospora echinospora genes encoding for biosynthesis of calicheamicin and self-resistance thereto
09/04/2003WO2002079238A3 Protein disulfide isomerase and abc transporter homologous proteins involved in the regulation of energy homeostasis
09/04/2003WO2002070468A3 Novel benzamidine derivatives having anti-inflammatory and immunosuppressive activity
09/04/2003WO2002064792A3 Molecules for disease detection and treatment
09/04/2003WO2002055698A3 Transcriptional mediators of blood vessel development and endothelial differentiation
09/04/2003WO2002053775A3 Identification of genetic determinants of polymorphic cyp3a5 expression
09/04/2003WO2002052020A3 Regulation of human carboxypeptidase a
09/04/2003WO2002052002A3 Immunomodulatory polynucleotides and methods of using the same
09/04/2003WO2002049501A3 Local regional chemotherapy and radiotherapy using in situ hydrogel
09/04/2003WO2002046426A3 Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor
09/04/2003WO2002045708A3 Use of zwitterionic polysaccharides for the specific modulation of immune processes
09/04/2003WO2002036807A3 Compositions and methods relating to breast specific genes and proteins
09/04/2003WO2002020769A9 Human and mouse targeting peptides identified by phage display
09/04/2003WO2002008456A3 Method for identifying metastatic tumor cells
09/04/2003WO2001092299A3 Adenovirus particles with mutagenized fiber proteins
09/04/2003WO2001081622A3 Diagnosis of diseases associated with dna repair
09/04/2003WO2001076451A3 Diagnosis of diseases associated with metabolism
09/04/2003WO2001066595A9 Human fgf-23 gene and gene expression products
09/04/2003WO2001057261A9 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides
09/04/2003WO2000067776A9 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
09/04/2003US20030167525 Desaturase genes and uses thereof
09/04/2003US20030167502 Human monoclonal antibodies to dendritic cells
09/04/2003US20030167496 Transgenic non-human mammals carrying human pituitary tumor transforming gene (PTTG) sequences
09/04/2003US20030167033 Systems and methods for photodynamic therapy
09/04/2003US20030167006 Ultrasound contrast using halogenated xanthenes
09/04/2003US20030166989 Method of radiotherapy
09/04/2003US20030166945 Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
09/04/2003US20030166911 Hybrid nucleic acids; genetic engineering
09/04/2003US20030166910 Bone morphogenic protein
09/04/2003US20030166902 Hybrid; process control; genetic engineering
09/04/2003US20030166899 Antiinflammatory agents; antiarthritic agents; anticancer agents
09/04/2003US20030166897 Diagnosis, therapy cancer; transgenic animal
09/04/2003US20030166876 Method of treating cancer including administering a human chimeric antibody specific for the ganglioside GD3
1 ... 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 ... 2211